EUVIMEDEUVIMED entdecken
Crossref

BI-3231, an enzymatic inhibitor of HSD17B13, reduces lipotoxic effects induced by palmitic acid in murine and human hepatocytes

Lucia Alcober-Boquet, Nico Kraus iD, Lisa Sophie Huber, Rajkumar Vutukuri, Dominik C Fuhrmann, Claudia Stross, Liliana Schaefer iD, Klaus Scholich, Stefan Zeuzem, Albrecht Piiper, Marcel H Schulz, Jonel Trebicka iD und 2 weitere

American Journal of Physiology-Cell Physiology · 2024

DOI: 10.1152/ajpcell.00413.2023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Physiology-Cell Physiology, 2024. Verfasst von Lucia Alcober-Boquet und 13 weiteren Autor:innen. Beteiligte Einrichtung: Medical Clinic 1, Goethe University Frankfurt, University Hospital, Frankfurt, Germany. Hauptthemen laut MEDLINE: Palmitic Acid, Fatty Liver. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Landes-Offensive zur Entwicklung Wissenschaftlich-ökonomischer Exzellenz, EnABLE Cluster, SFB1177.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) is a lipid droplet protein primarily expressed in the liver hepatocytes. HSD17B13 is associated with the clinical outcome of chronic liver diseases and is therefore a target for the development of drugs. Here, we demonstrate the promising therapeutic effect of BI-3231 as a potent inhibitor of HSD17B13 based on its ability to inhibit triglyceride accumulation in lipid droplets (LDs), restore lipid metabolism and homeostasis, and increase mitochondrial activity in vitro.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Palmitic AcidFatty LiverHumansAnimalsMiceEnzyme InhibitorsHepatocytesTriglycerides

Stichwörter der Autor:innen

17-β-hydroxysteroid dehydrogenase (HSD17B13)BI-3231lipid dropletlipid metabolismsteatotic liver disease (SLD)

Substanzen

Palmitic AcidEnzyme InhibitorsTriglycerides

Autor:innen und Institutionen

  • Medical Clinic 1, Goethe University Frankfurt, University Hospital, Frankfurt, Germany.
  • Faculty of Medicine, Institute of Pharmacology and Toxicology, Goethe University Frankfurt, Frankfurt, Germany.
  • Faculty of Medicine, Institute of Biochemistry I, Goethe University Frankfurt, Frankfurt, Germany.
  • Faculty of Medicine, Institute of Clinical Pharmacology, Goethe University Frankfurt, Frankfurt, Germany.
  • Faculty of Medicine, Institute of Cardiovascular Regeneration, Goethe University Frankfurt, Frankfurt, Germany.
  • Department of Internal Medicine B, University Hospital Münster, Münster, Germany.

ORCID-Profile: Nico Kraus, Liliana Schaefer, Jonel Trebicka, Christoph Welsch, Cristina Ortiz

Förderung

  • Landes-Offensive zur Entwicklung Wissenschaftlich-ökonomischer Exzellenz
  • EnABLE Cluster
  • SFB1177
  • SFB1039
  • SFB 1177
  • SFB 1039
  • Landes-Offensive zur Entwicklung Wissenschaftlich-ökonomischer Exzellenz (LOEWE) of the State of Hessen

Zitieren

APA

Alcober-Boquet, L., Kraus, N., Huber, L. S., Vutukuri, R., Fuhrmann, D. C., Stross, C., Schaefer, L., Scholich, K., Zeuzem, S., Piiper, A., Schulz, M. H., Trebicka, J., Welsch, C., & Ortiz, C. (2024). BI-3231, an enzymatic inhibitor of HSD17B13, reduces lipotoxic effects induced by palmitic acid in murine and human hepatocytes. American Journal of Physiology-Cell Physiology. https://doi.org/10.1152/ajpcell.00413.2023

Vancouver

Alcober-Boquet L, Kraus N, Huber LS, Vutukuri R, Fuhrmann DC, Stross C, et al. BI-3231, an enzymatic inhibitor of HSD17B13, reduces lipotoxic effects induced by palmitic acid in murine and human hepatocytes. American Journal of Physiology-Cell Physiology. 2024. doi:10.1152/ajpcell.00413.2023

BibTeX
@article{AlcoberBoquet2024,
  author = {Alcober-Boquet, Lucia and Kraus, Nico and Huber, Lisa Sophie and Vutukuri, Rajkumar and Fuhrmann, Dominik C and Stross, Claudia and Schaefer, Liliana and Scholich, Klaus and Zeuzem, Stefan and Piiper, Albrecht and Schulz, Marcel H and Trebicka, Jonel and Welsch, Christoph and Ortiz, Cristina},
  title = {BI-3231, an enzymatic inhibitor of HSD17B13, reduces lipotoxic effects induced by palmitic acid in murine and human hepatocytes},
  journal = {American Journal of Physiology-Cell Physiology},
  year = {2024},
  doi = {10.1152/ajpcell.00413.2023}
}
Kostenlos starten →